Last reviewed · How we verify
Combination lysine acetylsalicylate - clopidogrel
Combination lysine acetylsalicylate - clopidogrel is a Antiplatelet agent combination Small molecule drug developed by University Hospital, Bordeaux. It is currently in Phase 3 development for Acute coronary syndrome, Secondary prevention of cardiovascular events post-acute coronary syndrome.
This combination inhibits platelet aggregation through two complementary pathways: lysine acetylsalicylate irreversibly blocks thromboxane A2 synthesis, while clopidogrel inhibits ADP-mediated platelet activation.
This combination inhibits platelet aggregation through two complementary pathways: lysine acetylsalicylate irreversibly blocks thromboxane A2 synthesis, while clopidogrel inhibits ADP-mediated platelet activation. Used for Acute coronary syndrome, Secondary prevention of cardiovascular events post-acute coronary syndrome.
At a glance
| Generic name | Combination lysine acetylsalicylate - clopidogrel |
|---|---|
| Sponsor | University Hospital, Bordeaux |
| Drug class | Antiplatelet agent combination |
| Target | Cyclooxygenase-1 (COX-1) and P2Y12 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Lysine acetylsalicylate (aspirin) acetylates cyclooxygenase-1, preventing thromboxane A2 production and platelet aggregation. Clopidogrel is a P2Y12 receptor antagonist that blocks ADP-induced platelet activation. Together, they provide dual antiplatelet effects through distinct mechanisms, reducing thrombotic events more effectively than monotherapy.
Approved indications
- Acute coronary syndrome
- Secondary prevention of cardiovascular events post-acute coronary syndrome
Common side effects
- Bleeding
- Gastrointestinal hemorrhage
- Dyspepsia
- Bruising
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Combination lysine acetylsalicylate - clopidogrel CI brief — competitive landscape report
- Combination lysine acetylsalicylate - clopidogrel updates RSS · CI watch RSS
- University Hospital, Bordeaux portfolio CI
Frequently asked questions about Combination lysine acetylsalicylate - clopidogrel
What is Combination lysine acetylsalicylate - clopidogrel?
How does Combination lysine acetylsalicylate - clopidogrel work?
What is Combination lysine acetylsalicylate - clopidogrel used for?
Who makes Combination lysine acetylsalicylate - clopidogrel?
What drug class is Combination lysine acetylsalicylate - clopidogrel in?
What development phase is Combination lysine acetylsalicylate - clopidogrel in?
What are the side effects of Combination lysine acetylsalicylate - clopidogrel?
What does Combination lysine acetylsalicylate - clopidogrel target?
Related
- Drug class: All Antiplatelet agent combination drugs
- Target: All drugs targeting Cyclooxygenase-1 (COX-1) and P2Y12 receptor
- Manufacturer: University Hospital, Bordeaux — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Acute coronary syndrome
- Indication: Drugs for Secondary prevention of cardiovascular events post-acute coronary syndrome
- Compare: Combination lysine acetylsalicylate - clopidogrel vs similar drugs
- Pricing: Combination lysine acetylsalicylate - clopidogrel cost, discount & access